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Impact of Baseline Anemia in Patients With Acute Coronary
Syndromes Undergoing Percutaneous Coronary Intervention:
A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial
Axel Wester, MD; Rubina Attar, BMSc; Moman Aladdin Mohammad, MD; Pontus Andell, MD, PhD; Robin Hofmann, MD, PhD;
Jens Jensen, MD, PhD; Karolina Szummer, MD, PhD; David Erlinge, MD, PhD; Sasha Koul, MD, PhD
Background-—The impact of baseline anemia in a contemporary acute coronary syndrome (ACS) population undergoing
percutaneous coronary intervention in the era of predominant radial artery access, potent P2Y12 inhibition, and rare use of
glycoprotein IIb/IIIa inhibitors has not been adequately studied.
Methods and Results-—ACS patients who underwent percutaneous coronary intervention between 2014 and 2016 in the VALIDATE-
SWEDEHEART (Bivalirudin Versus Heparin in ST-Segment and Non–ST-Segment Elevation Myocardial Infarction in Patients onModern
Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease
Evaluated According to Recommended Therapies Registry) trial without missing values for hemoglobin were included (n=5482).
Mortality, myocardial reinfarction, and major bleeding at 180 days were assessed using Cox regression models and propensity score
matching. All studied comorbidities were more common in ACS patients who had anemia (n=792). ACS patients with anemia
had higher rates of 180-day mortality (6.9% versus 2.1%; hazard ratio, 1.9; 95% CI, 1.3–2.7; P<0.001), myocardial reinfarction (4.3%
versus 1.9%; hazard ratio, 1.7; 95% CI, 1.1–2.7; P=0.013), and major bleeding (13.4% versus 8.2%; hazard ratio, 1.3; 95% CI, 1.0–1.6;
P=0.041). The resultsweremost evident in patientswith ahemoglobin value<100 g/L,whohadanearly 10 timeshighermortality rate.
Conclusions-—Baseline anemia in ACS patients undergoing percutaneous coronary intervention, treated according to current
practice including routine radial artery access, constitutes a high-risk feature for both ischemic events, bleeding events, and
mortality. A multidisciplinary approach is warranted to maximize benefit and minimize patient risk.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02311231. ( J Am Heart Assoc. 2019;8:
e012741. DOI: 10.1161/JAHA.119.012741.)
Key Words: acute coronary syndromes • anemia • mortality • VALIDATE-SWEDEHEART
D espite advances in the field of acute coronary care,major bleedings following percutaneous coronary inter-
vention (PCI) still constitute a major clinical problem.1 It has
been suggested that a major bleeding carries the same
prognostic impact as a new myocardial infarction (MI) during
the first year after an acute coronary syndrome (ACS).2 The
HORIZONS-AMI (Harmonizing Outcomes With Revascu-
larization and Stents in Acute Myocardial Infarction) trial
demonstrated more than a decade ago that bivalirudin
reduced mortality in patients with ST-segment–elevation
myocardial infarction (STEMI) undergoing primary percuta-
neous coronary intervention, compared with heparin plus
glycoprotein IIb/IIIa inhibitors (GPIs).3 This was in part due to
a reduction in major bleedings.3,4 Both non–access site and
access site major bleedings increase mortality; however,
radial artery access essentially removes the risk of excess
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mortality associated with major access site bleedings.5,6 In
parallel with the increased use of radial artery access, acute
medical care of ACS patients has also improved with the
advent of potent P2Y12 inhibitors.7,8
Baseline anemia, defined according to the World Health
Organization,9 is present in nearly 20% of ACS patients.10,11
ACS patients with anemia are older and more often present
with previous cardiovascular disease, diabetes mellitus, a
history of major bleeding, and malignancy, compared with
those without anemia.10–19 Having anemia at baseline
therefore identifies both patients at high risk of bleeding
and those at high risk for ischemic events. In fact, anemia in
ACS patients is not only associated with overall increased
mortality and bleeding but in some studies also associated
with increased rates of MI.10,11
The vast majority of studies investigating the impact of
baseline anemia on hard clinical events have been performed in
an era of either extensive GPI use or with limited radial artery
use. The recent VALIDATE-SWEDEHEART (Bivalirudin Versus
Heparin in ST-Segment and Non–ST-Segment Elevation
Myocardial Infarction in Patients on Modern Antiplatelet
Therapy in the Swedish Web System for Enhancement and
Development of Evidence-Based Care in Heart Disease Evalu-
ated According to Recommended Therapies Registry) trial
compared bivalirudin to heparin monotherapy in ACS patients
undergoing PCI.20 The patients enrolled in the trial constituted a
modern ACS population with high use of radial artery access
(90.3%) as well as high use of modern P2Y12 inhibitors
(ticagrelor 94.9%, prasugrel 2.1%, or cangrelor 0.3%). Further-
more, only bailout use of GPI was allowed (2.6%).20 The impact
of anemia at baseline in such a patient cohort, treated according
to contemporary strategies has so far not been adequately
assessed. The aim of the current study was therefore to
evaluate the prognostic value of baseline anemia in ACS
patients enrolled in the VALIDATE-SWEDEHEART trial.
Methods
Study Population
Data, methods and materials used to conduct this research
can be made available after clearance by the VALIDATE
steering committee. The study design of the VALIDATE-
SWEDEHEART trial has already been described in detail.20,21
In short, VALIDATE-SWEDEHEART was a registry-based,
multicenter, prospective, randomized, controlled, and open-
label clinical trial evaluating the efficacy and safety of heparin
monotherapy versus bivalirudin in ACS patients undergoing
PCI. The trial included patients presenting with STEMI or non-
STEMI (NSTEMI) between 2014 and 2016 and for whom PCI
was planned at one of the 25 participating Swedish centers.
Treatment with ticagrelor, prasugrel, or cangrelor before PCI
was mandatory and only bailout use of GPI was allowed. The
SWEDEHEART registry was used as case-report form for
randomization and for follow-up. A total of 6006 patients
underwent randomization in the VALIDATE-SWEDEHEART trial,
and all patients without missing values for hemoglobin
(n=5482) were included in the present study (Figure 1).
Baseline anemia was defined in accordance with the World
Health Organization as a hemoglobin value <130 g/L for men
and <120 g/L for women.9 The hemoglobin values in the
cohort represent the first acquired hemoglobin for each
patient, meaning that the blood tests were performed at the
Figure 1. Flowchart of study inclusion.
Clinical Perspective
What Is New?
• Baseline anemia in acute coronary syndrome patients who
undergo percutaneous coronary intervention and are treated
according to current practice with >90% use of radial artery
access, >97% potent P2Y12 inhibitors during percutaneous
coronary intervention, and <3% glycoprotein IIb/IIIa inhibi-
tors was associated with higher rates of 180-day mortality,
myocardial reinfarction, and major bleeding.
• Patients with severe anemia (a hemoglobin value <100 g/L)
had a nearly 10 times higher mortality rate, 6 times higher
rate of myocardial reinfarction, and 3 times higher rate of
major bleeding at 180 days.
What Are the Clinical Implications?
• Our results indicate that anemia constitutes a high-risk
feature in patients with acute coronary syndromes, despite
treatment with contemporary therapies, including high use
of radial artery access.
• In complex patients with anemia and concomitant coronary
disease, a multidisciplinary approach is warranted to
maximize benefit and minimize patient risk.
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emergency department on arrival or in relation to the PCI
procedure in those STEMI patients who went directly to the
catheterization lab. The VALIDATE-SWEDEHEART trial and
subgroup analyses were approved by the ethics committee at
Lund University and the Swedish Medical Products Agency. All
patients provided written informed consent to participate in
the trial.
End Points
The primary end point was death from any cause at 180 days.
Secondary end points were myocardial reinfarction, major
bleeding, definite stent thrombosis, and stroke at 180 days.
MI was defined according to the third universal definition,22
and major bleeding was defined as type 2, 3, or 5 according to
the Bleeding Academic Research Consortium scale.20 Further
analyses were done on cause of death, divided into cardio-
vascular death, fatal bleeding, or other causes.
End point screening and adjudication
Research nurses screened for clinical end point events by
contacting the patients or first-degree relatives by telephone
7 and 180 days after PCI. If a patient was suspected to have
had a clinical end point event (ie, death, myocardial reinfarc-
tion, major bleeding, or stroke), the patient’s healthcare
records were subjected to central blinded adjudication to
determine both the cause of the event and the date of the
event according to prespecified criteria. Time to event was
calculated using calendar days with date of randomization as
time point zero. If the patient or relatives could not be
contacted after the nurses had placed repeated telephone
calls and mailed a letter, information was collected through
review of hospital records.20
Statistical Analyses
Differences between categorical variables were analyzed with
the chi-square test and continuous variables were compared
using the Mann–Whitney U test. Kaplan–Meier event rates
were analyzed to compare unadjusted primary and secondary
end points between groups. Patients who were lost to follow-
up were censored at the last contact with the patient.20
Adjustments for confounders were made using multivariable
Cox regression models as well as propensity score matching.
We also performed landmark analyses for mortality and major
bleeding to distinguish between short- and long-term effects.
Statistical significance was defined as a 2-tailed P<0.05.
Analyses were performed in IBM SPSS (Armonk, NY: IBM
Corp.) (version 25), R (R Foundation for Statistical Computing,
Vienna, Austria) (version 3.4.4), Stata (Statacorp, TX)
(GraphPad Software, San Diego, California USA) (version
15.1), or GraphPad Prism (version 8.0.2).
Propensity score matching
A propensity score (PS) for baseline anemia was calculated
using the variables age, sex, STEMI, medical history of kidney
dysfunction, diabetes mellitus, coronary artery disease, and
heart failure to achieve a good balancing of baseline
differences. PS matching was performed in a 1:1 fashion.
End points were subsequently analyzed using univariable Cox
regression. In separate sensitivity analyses, downstream
adjustments were made for body mass index (BMI).
Multiple imputation and subsequent multivariable Cox
regression
Baselines differences that were associated with anemia and
with worse clinical outcomes were identified a priori and
adjusted for. These variables were age, sex, BMI, STEMI,
medical history of kidney dysfunction, hyperlipidemia, hyper-
tension, diabetes mellitus, current smoking, coronary artery
disease, stroke, heart failure, Killip class, hours from symptom
onset to PCI, radial artery access during PCI, use of potent
P2Y12 inhibitors (ticagrelor, prasugrel, or cangrelor) during
PCI, and blood transfusion during the hospital stay. In the
original data set, 1440 (26.3%) cases had missing values for
at least 1 of these variables. Data were assumed to be
missing at random, based on Little’s Missing Completely at
Random test as well as logistic regression modeling. Multiple
imputation was performed for missing data by using 10
imputations and 10 iterations for every imputation. In
subsequent multivariable Cox regression analysis, adjust-
ments were made for all variables mentioned above. Kidney
dysfunction was defined as an estimated glomerular filtration
rate <60 mL/min per 1.73 m2. Coronary artery disease was
defined as previous MI, previous PCI, or previous coronary
artery bypass grafting. The multivariable Cox regression
model for mortality was tested for proportionality of hazards
using Schoenfeld residuals.
Results
Patient Characteristics
Baseline anemia was present in 792 of 5482 ACS patients
(14.4%). Patients with anemia were older (P<0.001), more
often women (P=0.034), and had a lower BMI compared with
patients without anemia (P<0.001; Table 1). Furthermore,
patients with anemia more often had kidney dysfunction,
hyperlipidemia, previous hypertension, diabetes mellitus,
current smoking, previous coronary artery disease, previous
stroke, or a history of heart failure (all P<0.001). Patients with
anemia also more frequently presented with STEMI and Killip
class 3 or 4 than patients without anemia (P<0.001). The time
from symptom onset to PCI did not significantly differ
between nonanemic and anemic patients when analyzing
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Table 1. Characteristics of Patients With Acute Coronary Syndromes With and Without Anemia
No Anemia*
(n=4690)
Anemia*
(n=792) P Value
Missing or
Unknown, n (%)
Hemoglobin, median (IQR) 145 (137–154) 118 (112–125) <0.001 0 (0.0)
Age, y 0 (0.0)
Median (IQR) 67 (59–74) 74 (67–81) <0.001
≥65, n (%) 2695 (57.5) 642 (81.1) <0.001
Female, n (%) 1217 (25.9) 234 (29.5) 0.034 0 (0.0)
BMI, median (IQR) 27 (25–30) 26 (23–28) <0.001 563 (10.3)
Medical history, n (%)
Kidney dysfunction 598 (12.8) 244 (30.8) <0.001 8 (0.1)
Hyperlipidemia 1419 (30.3) 299 (37.8) <0.001 43 (0.8)
Hypertension 2351 (50.4) 475 (60.3) <0.001 27 (0.5)
Diabetes mellitus 702 (15.0) 198 (25.0) <0.001 14 (0.3)
Current smoker 1174 (25.7) 146 (19.1) <0.001 142 (2.6)
CAD 847 (18.1) 221 (27.9) <0.001 56 (1.0)
Previous MI 690 (14.7) 183 (23.1) <0.001
Previous PCI 639 (13.6) 156 (19.7) <0.001
Previous CABG 200 (4.3) 66 (8.3) <0.001
Stroke 170 (3.6) 51 (6.5) <0.001 26 (0.5)
Heart failure 142 (3.0) 60 (7.6) <0.001 120 (2.2)
STEMI, n (%) 2365 (50.4) 457 (57.7) <0.001 0 (0.0)
Killip class 3 or 4, n (%) 38 (0.8) 13 (1.6) 0.024 0 (0.0)
Hours from symptoms to PCI 592 (10.8)
STEMI, median (IQR) 3 (2–6) 3 (2–6) 0.482
NSTEMI, median (IQR) 31 (18–57) 35 (18–64) 0.177
Randomized to heparin, n (%) 2372 (50.6) 385 (48.6) 0.306 0 (0.0)
Potent P2Y12 inhibitors
during PCI, n (%)
4566 (98.9) 749 (96.9) <0.001 92 (1.7)
Radial access, n (%) 4276 (91.2) 680 (85.9) <0.001 0 (0.0)
Peak high-sensitivity cardiac troponin T,
median (IQR)
628 (146–2490) 1013 (169–3251) 0.001 1475 (26.9)
LVEF during hospital stay, n (%) <0.001 700 (12.8)
≥50% 2672 (65.0) 371 (55.4)
49%–40% 879 (21.4) 174 (26.0)
39%–30% 451 (11.0) 91 (13.6)
<30% 110 (2.7) 34 (5.1)
Blood transfusion during
hospital stay, n (%)
4 (0.1) 4 (0.5) 0.013 39 (0.7)
Discharge medications, n (%)
Aspirin 4483 (97.0) 713 (93.2) <0.001 104 (1.9)
Other antiplatelets <0.001 97 (1.8)
Clopidogrel 339 (7.3) 92 (12.0)
Prasugrel 46 (1.0) 9 (1.2)
Ticagrelor 4160 (90.0) 639 (83.5)
Continued
DOI: 10.1161/JAHA.119.012741 Journal of the American Heart Association 4
Baseline Anemia in ACS Wester et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 20, 2019
STEMI (median time, 3 hours in both groups) and NSTEMI
patients separately (31 hours versus 35 hours, respectively).
Radial access PCI and potent P2Y12 inhibitors were less
frequently used in patients with anemia (P<0.001). Patients
with anemia had a higher median peak value of high-sensitivity
cardiac troponin T and a lower left ventricular ejection fraction
during their hospital stay than patients without anemia (both
P=0.001). Furthermore, patients with anemia more often
received blood transfusion (P=0.013). At discharge, patients
with anemia less often received evidence-based discharge
medications such as aspirin and ticagrelor (Table 1). After PS
matching, baseline variables were equalized between groups
(Table 2). However, differences remained regarding BMI
(which was analyzed in separate sensitivity analyses).
Mortality
Patients with ACS and anemia at baseline had a higher
unadjusted mortality rate at 180 days compared with patients
without anemia (6.9% and 2.1,% respectively; P<0.001;
Figure 2A). After multiple imputation, and subsequent multi-
variable adjustments for confounding factors, patients with
anemia still had a higher hazard ratio (HR) for 180-day
mortality (HR, 1.9; 95% CI, 1.3–2.7; P<0.001). Results were
consistent in the PS matched cohort (HR, 2.3; 95% CI, 1.4–
3.7; P=0.001; Table 3; Figure S1A).
Myocardial Reinfarction
Patient with ACS and anemia more often experienced
myocardial reinfarction (4.3% versus 1.9%; P<0.001; Fig-
ure 2B). Results were unchanged after multiple imputation
with multivariable adjustments (HR, 1.7; 95% CI, 1.1–2.7;
P=0.013) as well as in PS matched patients (HR, 2.0; 95% CI,
1.1–3.7; P=0.022; Table 3; Figure S1B).
Major Bleeding
ACS patients with anemia experienced higher rates of major
bleeding than patients without anemia (13.4% versus 8.2%;
P<0.001; Figure 2C). Results were consistent after multiple
imputation with multivariable adjustments (HR, 1.3; 95% CI,
1.0–1.6; P=0.041) and in PS matched patients (HR, 1.4; 1.0–
1.9; P=0.037; Table 3; Figure S1C).
Other End Points
No difference was found in event rates of definite stent
thrombosis between patients with and without anemia
(0.8% and 0.6%, respectively; P=0.46; Figure 2D). PS
matching showed similar results (HR, 1.5; 95% CI, 0.4–
5.4; P=0.51; Figure S1D). However, patients with anemia
experienced higher rates of stroke (2.0% compared with
0.7%; P<0.001; Figure 2E), which was consistent in PS
matched patients (HR, 2.9; 95% CI, 1.0–8.0; P=0.042;
Table 3; Figure S1E).
Sensitivity and Subgroup Analyses
Landmark analyses in patients who survived the first
7 days were performed (Figure 3). Both mortality (4.5%
versus 1.2%; P<0.001) and major bleeding (6.9% versus
4.9%; P=0.026) were significantly increased in the 7-day
landmark analyses for ACS patients with anemia. The
mortality curve also showed continued separation over
time (Figure 3A). Results were also consistent when
anemia was stratified according to severity (Figure 4).
Patients with anemia with a hemoglobin <100 g/L had a
nearly 10 times higher mortality rate, 6 times higher rate
of myocardial reinfarction, and 3 times higher rate of
major bleeding, compared with patients with normal
hemoglobin values. High hemoglobin values (>150 g/L)
were not associated with worse outcome compared with
normal hemoglobin values. Hemoglobin was also analyzed
as a continuous variable for patients with a hemoglobin
value between 90 (to exclude outliers, based on visual
inspection of a histogram of the hemoglobin level distri-
bution) and 140 (as greater hemoglobin levels have
previously been associated with increased risk of adverse
Table 1. Continued
No Anemia*
(n=4690)
Anemia*
(n=792) P Value
Missing or
Unknown, n (%)
Warfarin or NOAC 291 (6.3) 69 (9.0) 0.014 102 (1.9)
ACEI or ARB 4106 (88.9) 651 (85.1) 0.009 98 (1.8)
Beta-blockers 4217 (91.3) 652 (85.2) <0.001 98 (1.8)
Statins 4522 (97.9) 732 (95.7) <0.001 97 (1.8)
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease;
IQR, interquartile range; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NOAC, novel oral anticoagulant; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI,
percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction.
*Baseline anemia was defined in accordance with the World Health Organization as a hemoglobin value <130 g/L for men and <120 g/L for women.
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events).12 This analysis yielded an HR of 0.95 (95% CI,
0.93–0.96; P<0.001) for each grams per liter increase of
hemoglobin with regard to 180-day mortality. In patients
with baseline anemia, randomized treatment (heparin
versus bivalirudin) did not affect rates of mortality
(P=0.36), myocardial reinfarction (P=0.89), or major
bleeding (P=0.92) at 180 days (Table S1). Patients with
anemia did not seem to benefit more from radial artery
access during PCI than patients without anemia regarding
180-day mortality (Pinteraction=0.437) or major bleeding
(Pinteraction=0.254). Results after PS matching did not
change when downstream adjustments were made for BMI
(Table S2). Moreover, we analyzed causes of death and
found that patients with anemia were 3 times as likely to
die from cardiovascular causes, 5 times as likely to die
from fatal bleeding, and 4 times as likely to die from other
causes (noncardiovascular and nonfatal bleeding;
Table 4). Among the patients with anemia who died within
180 days (n=54), fatal bleeding and other causes (non-
cardiovascular and nonfatal bleeding) represented a larger
proportion of deaths than for patients without anemia who
experienced death (n=96; Figure 5).
Table 2. Patient Characteristics After Propensity Score Matching
No Anemia (n=762) Anemia* (n=762) P Value
Hemoglobin, median (IQR) 142 (135–151) 118 (112–125) <0.001
Age, y
Median (IQR) 74 (67.75–81) 74 (67–81) 0.518
≥65, n (%) 628 (82.4) 617 (81.0) 0.466
Female, n (%) 231 (30.3) 225 (29.5) 0.737
BMI, median (IQR) 27 (24–30) 26 (23–28) <0.001
Medical history, n (%)
Kidney dysfunction 236 (31.0) 236 (31.0) >0.999
Hyperlipidemia 283 (37.4) 289 (38.4) 0.690
Hypertension 478 (63.1) 451 (59.5) 0.155
Diabetes mellitus 165 (21.7) 189 (24.8) 0.145
Current smoker 128 (17.3) 138 (18.8) 0.453
CAD 195 (25.6) 213 (28.0) 0.298
Stroke 38 (5.0) 49 (6.5) 0.217
Heart failure 56 (7.3) 60 (7.9) 0.699
STEMI, n (%) 441 (57.9) 436 (57.2) 0.796
Killip class 3 or 4, n (%) 13 (1.7) 13 (1.7) >0.999
Hours from symptoms to PCI
STEMI, median (IQR) 3 (2–6) 3 (2–6) 0.743
NSTEMI, median (IQR) 33 (21–62) 34 (18–64) 0.647
Potent P2Y12 inhibitors during PCI, n (%) 734 (98.1) 720 (96.8) 0.097
Radial artery access, n (%) 677 (88.8) 655 (86.0) 0.089
Peak high-sensitivity cardiac troponin T, median (IQR) 763 (161–3252) 1017 (184–3217) 0.388
LVEF during hospital stay, n (%) 0.854
≥50% 380 (57.2) 356 (55.4)
49%–40% 161 (24.2) 169 (26.3)
39%–30% 90 (13.6) 85 (13.2)
<30% 33 (5.0) 33 (5.1)
Blood transfusion during hospital stay, n (%) 2 (0.3) 4 (0.5) 0.434
BMI indicates body mass index; CAD, coronary artery disease; IQR, interquartile range; LVEF, left ventricular ejection fraction; NSTEMI, non–ST-segment–elevation myocardial infarction;
PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction.
*Baseline anemia was defined in accordance with the World Health Organization as a hemoglobin value <130 g/L for men and <120 g/L for women.
DOI: 10.1161/JAHA.119.012741 Journal of the American Heart Association 6
Baseline Anemia in ACS Wester et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 20, 2019
Discussion
The main findings of our study were that baseline anemia in
patients with ACS, treated according to contemporary
practice with radial artery access, mandatory use of
modern P2Y12 inhibitors, and low use of GPI, was
associated with a large excess risk of mortality at
180 days. Patients with anemia also experienced higher
risk of myocardial reinfarction as well as major bleeding
and stroke. No difference in definite stent thrombosis was
seen. The results were consistent over time in landmark
analyses. A strong correlation between anemia severity and
A B
C D
E
Figure 2. Kaplan–Meier failure functions for mortality (A), myocardial reinfarction (B), major bleeding (C), definite stent thrombosis (D), and
stroke (E), at 180 days in acute coronary syndrome patients with and without anemia.
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increased mortality, myocardial reinfarction, and major
bleeding rates was seen, with especially a hemoglobin
level <100 g/L being associated with an overall high
clinical event rate. All causes of death (cardiovascular
death, fatal bleedings, and other causes of death) were
increased.
A B
Figure 3. Landmark analysis at 7 days, for mortality (A) and major bleeding (B), in acute coronary syndrome patients with and without anemia.
Table 3. End Points at 180 Days
No Anemia
(n=4690)
Anemia*
(n=792) 95% CI P Value
Missing or
Unknown, n (%)
Mortality
Kaplan–Meier event rates, n (%) 96 (2.1) 54 (6.9) <0.001 0 (0.0)
Unadjusted HR 1.0 3.4 2.5–4.8 <0.001 0 (0.0)
Multivariable adjusted HR after multiple imputation 1.0 1.9 1.3–2.7 <0.001 0 (0.0)
Propensity score matching HR 1.0 2.3 1.4–3.7 0.001 0 (0.0)
Reinfarction
Kaplan–Meier event rates, n (%) 88 (1.9) 32 (4.3) <0.001 0 (0.0)
Unadjusted HR 1.0 2.3 1.5–3.4 <0.001 0 (0.0)
Multivariable adjusted HR after multiple imputation 1.0 1.7 1.1–2.7 0.013 0 (0.0)
Propensity score matching HR 1.0 2.0 1.1–3.7 0.022 0 (0.0)
Major bleeding†
Kaplan–Meier event rates, n (%) 377 (8.2) 102 (13.4) <0.001 0 (0.0)
Unadjusted HR 1.0 1.7 1.4–2.1 <0.001 0 (0.0)
Multivariable adjusted HR after multiple imputation 1.0 1.3 1.0–1.6 0.041 0 (0.0)
Propensity score matching HR 1.0 1.4 1.0–1.9 0.037 0 (0.0)
Definite stent thrombosis
Kaplan–Meier event rates, n (%) 26 (0.6) 6 (0.8) 0.460 0 (0.0)
Propensity score matching HR 1.0 1.5 0.4–5.4 0.510 0 (0.0)
Stroke
Kaplan–Meier event rates, n (%) 32 (0.7) 15 (2.0) <0.001 0 (0.0)
Propensity score matching HR 1.0 2.9 1.0–8.0 0.042 0 (0.0)
HR indicates hazard ratio.
*Baseline anemia was defined in accordance with the World Health Organization as a hemoglobin value <130 g/L for men and <120 g/L for women.
†Major bleeding was defined as 2, 3, or 5 on the Bleeding Academic Research Consortium scale.
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Results in Context With Previous Studies
The association between baseline anemia andmortality has been
studied and validated in several trials, both in the general
population23 and in coronary arterydisease.10–19However, these
trials havemostly been performed in an era of extensive usage of
GPI, which currently is not recommended as standard practice
because of excess bleeding risk.24 Furthermore, these studies
were carriedoutwhen the radial arterywasnot thedefault access
route.24 Both reducing the use of GPI and using primarily the
radial artery as access route has in multiple randomized trials
been associated with less serious bleedings.3,6 However, the
usage of more potent P2Y12 inhibition could in theory increase
bleeding rates, especially in patients with anemia.7,8 Therefore,
we aimed to evaluate how baseline anemia translates into hard
clinical outcomes in an era of >90% radial artery access and only
bailout use of GPI (<3%) but with modern P2Y12 inhibition. Our
results indicate that baseline anemia still constitutes a highly
predictive factor for total mortality in this clinical setting.
Regarding myocardial reinfarction, previous studies have
reported conflicting data. Whereas some studies report an
increase in myocardial reinfarction,10,11,14 some studies do not
show any association.12,13,17,25 Our results indicate an increase
in myocardial reinfarction in patients with baseline anemia. We
also found that the left ventricular ejection fraction of patients
with anemia during their hospital stay was lower compared with
that of patients without anemia, which might be indicative of a
larger infarct size or area at ischemic risk. Likewise, patients with
anemia had higher peak values of high-sensitivity cardiac
troponin T, which is a strong predictor of infarct size and systolic
dysfunction at 6 months.26 Moreover, we found an increase in
bleeding events in patients with anemia, despite low use of GPI
and >85% radial artery access in this patient group. Notably, the
bleeding risk was particularly high in patients with a hemoglobin
value <100 g/L, which is consistent with the PRECISE-DAPT
(Predicting Bleeding Complications in Patients Undergoing Stent
Implantation and Subsequent Dual Antiplatelet Therapy) risk
score.27 The landmark analyses suggest that there is a continued
increased bleeding risk even after the acute phase of MI.
However, the majority of bleedings occurred within the first
week, despite the default radial access use and low GPI use.
Some studies have shown a J-shaped association between
hemoglobin levels and outcomes.12 However, this could not be
demonstrated from our data, where only low hemoglobin levels
appeared to be linked with worse outcomes. Caution should be
applied when adding potent antithrombotic agents to patients
with anemia during their hospital stay. However, this must be
balanced with the increased risk of MI of this patient group.
Mechanisms Behind Mortality, Myocardial
Reinfarction, and Major Bleeding
Baseline hemoglobin level may be a surrogate marker of
comorbidities, such as malignancies, that are associated with
increased bleeding rate as well as risk of thromboembolic
Figure 4. Event rates at 180 days for mortality (green), reinfarction (blue), and major bleeding (red),
stratified by hemoglobin level categories in acute coronary syndrome patients: severe anemia (hemoglobin
<100 g/L); moderate anemia (hemoglobin 100–109 g/L); mild anemia (hemoglobin 110–129 g/L for men
and 110–119 g/L for women); normal hemoglobin (130–150 g/L for men and 120–150 g/L for women);
and high hemoglobin (>150 g/L).
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events.28 Anemia could also be a marker of inflammatory
disorders that are in turn associated with increased ischemic
risk.28,29 Furthermore, anemia could also be suggestive of an
ongoing occult gastrointestinal bleeding or an increased
propensity for bleeding attributable to coagulopathies.11 In
accordance with this, fatal bleeding was in our study 5 times
more common in patients with anemia. Moreover, patients
with anemia more often received blood transfusion, which
has previously been described as a possible independent
factor for mortality in ACS patients.30 Other stipulated
mechanisms behind anemia and ischemic outcomes could be
a decreased oxygen-carrying capacity of the blood that
predisposes for ischemia and arrhythmias.12 Our data
suggest that patients with anemia also receive less optimal
guideline-directed discharge medication, including aspirin
and potent P2Y12 inhibitors, which could predispose to
downstream ischemic events. The factors mentioned above
may explain our finding that cardiovascular death causes
were 3 times as frequent in patients with anemia. This could
also be explained by a higher comorbidity burden of
cardiovascular risk factors, or discontinuation of antiplatelet
therapy due to bleeding events in patients with anemia,
which may generate consequential ischemic complications.31
Interestingly, radial access was less often used in patients
with anemia, highlighting that patients with anemia are a
sicker group, where puncture of the radial artery to a lesser
degree was deemed possible. This may be attributable to
more extensive arteriosclerosis or hemodynamic instability in
this patient group, and therefore a femoral approach might
have been preferred.
Limitations
Our study is an observational study, and causality between
anemia and worse outcomes is therefore uncertain. Further-
more, a larger sample size including more patients with
anemia could have shed further light on the topic of anemia
and clinical outcomes. More background knowledge of cause
of anemia could have added more information on mechanisms
behind anemia and worse clinical outcomes. In addition, we
Figure 5. The causes of death for acute coronary syndrome patients who died within 180 days from their
index myocardial infarction (n=150). Patients are divided into those who presented without baseline anemia
(n=96) and with baseline anemia (n=54).
Table 4. Causes of Death for Acute Coronary Syndrome
Patients With and Without Anemia
No Anemia
(n=4690)
Anemia*
(n=792) 95% CI P Value
Cardiovascular death cause
Kaplan–Meier
event rates,
n (%)
75 (1.6) 40 (5.2) <0.001
Unadjusted HR 1.0 3.3 2.2–4.8 <0.001
Fatal bleeding
Kaplan–Meier
event rates,
n (%)
5 (0.1) 4 (0.5) 0.009
Unadjusted HR 1.0 4.9 1.3–18.1 0.018
Other death cause
Kaplan–Meier
event rates,
n (%)
16 (0.3) 10 (1.4) <0.001
Unadjusted HR 1.0 3.9 1.8–8.6 0.001
HR indicates hazard ratio.
*Baseline anemia was defined in accordance with the World Health Organization as a
hemoglobin value <130 g/L for men and <120 g/L for women.
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lacked data on some potential confounders, including malig-
nancy, coagulopathies, and inflammatory disorders, which
could have contributed to the higher event rates in patients
with anemia. Finally, the hemoglobin value is subject to
natural variation due to variation of the intravasal plasma
volume that is subject to dehydration/diuretics as well as
volume infusion.
Conclusions
Our results indicate that anemia constitutes a high-risk
feature in patients with acute coronary syndromes despite
treatment with contemporary therapies, including high use
of radial artery access, potent P2Y12 inhibitors, and low use
of GPI. Especially anemia with a hemoglobin <100 g/L,
constitutes a strong negative predictive sign with a
substantially increased risk of death, myocardial reinfarction,
and major bleeding. The mechanisms are likely multifacto-
rial: Anemia can both be a marker of a sicker patient cohort
and have direct physiological consequences, but it may also
lead to a lesser degree of guideline-stipulated discharge
medications. Nevertheless, in complex patients with anemia
and concomitant coronary disease, a multidisciplinary
approach is warranted to maximize benefit and minimize
patient risk.
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Table S1. Kaplan-Meier event rates for patients with and without anemia who received heparin vs 
bivalirudin. 
 
No Anemia 
n=4690  p-value 
Anemia 
n=792  p-value 
 
Heparin 
n=2372 
  
Bivalirudin 
n=2318 
   
Heparin 
n=385 
  
Bivalirudin 
n=407 
   
Mortality n(%) 51(2.2) 45(2.0) 0.617 23(6.1) 31(7.8) 0.364 
Reinfarction n(%) 52(2.2) 36(1.6) 0.106 16(4.4) 16(4.2) 0.889 
Major bleeding n(%) 192(8.2) 185(8.1) 0.850 50(13.4) 52(13.3) 0.917 
*Baseline anemia was defined in accordance with WHO as a hemoglobin value <130 g/L for men and <120 g/L 
for women. †Major bleeding was defined as 2, 3, or 5, on the Bleeding Academic Research Consortium scale. 
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Table S2. Sensitivity analyses for endpoints at 180 days after propensity score matching with downstream 
adjustments for body mass index (BMI). 
 
No Anemia 
n=4690 
Anemia 
n=792 95% CI p-value 
Missing or 
unknown n(%) 
Mortality - hazard ratio 1.0 2.2 1.3-3.8 0.002 156(10.2) 
Reinfarction – hazard ratio 1.0 2.2 1.2-4.2 0.013 156(10.2) 
Major bleeding – hazard ratio 1.0 1.4 1.0-1.9 0.041 156(10.2) 
Definite stent thrombosis – hazard ratio 1.0 1.0 0.3-3.9 0.979 156(10.2) 
Stroke – hazard ratio 1.0 2.7 0.9-7.6 0.066 156(10.2) 
*Baseline anemia was defined in accordance with WHO as a hemoglobin value <130 g/L for men and <120 g/L 
for women. Major bleeding was defined as 2, 3, or 5, on the Bleeding Academic Research Consortium scale. 
†Abbreviations: CI=confidence interval 
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Figure S1. Kaplan-Meier failure functions for mortality (A), myocardial reinfarction (B), 
major bleeding (C), definite stent thrombosis (D), and stroke (E), at 180 days in acute 
coronary syndrome patients with and without anemia after propensity score matching. 
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